The third quarterly reports of listed pharmaceutical companies in 2022 have been disclosed one after another, and many results are good!

【Pharmaceutical Network Industry News】As of the close of trading on October 23, many A-share pharmaceutical companies, including Kangyuan Pharmaceutical, China Resources Sanjiu, and Laomin, released third-quarter performance reports or express reports, and most of them reported good
results 。 Kangyuan Pharmaceutical Kangyuan Pharmaceutical is the first pharmaceutical company to release three quarterly reports, the company released the first three quarters of 2022 performance report on October 9 this year: from January 1, 2022 to September 30, 2022, the company achieved operating income of 3.
125 billion yuan, a year-on-year increase of 20.
97%, net profit of 281 million yuan, a year-on-year increase of 35.
83%, and basic earnings per share of 0.
49 yuan
.
According to the data, Kangyuan Pharmaceutical is a company with the development of traditional Chinese medicine as the main body and actively deploys chemical drugs, biological drugs and other fields, and the company's main business involves the research and development, production and sales
of drugs.
China Resources 39 China Resources 39 released its performance report
for the first three quarters of 2022 on the evening of October 10.
From January to September 2022, the company achieved a total operating income of 12.
111 billion yuan, a year-on-year increase of 7.
53%; The net profit attributable to the shareholders of the listed company was 1.
952 billion yuan, a year-on-year increase of 11.
17%; The net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses was 1.
783 billion yuan, a year-on-year increase of 10.
08%.

According to the data, CR Sanjiu is mainly engaged in the research and development, production, sales and related health services
of pharmaceutical products.
The main products include 999 cold spirit, 999 dermatitis ping, reference injection, cephalosporin for injection, no-decoction Chinese medicine, Sanjiu stomach Tai granules, zhengtian pills, etc
.
The performance report released by the common people on October 16 shows that in the first three quarters of 2022, the company achieved operating income of 13.
776 billion yuan, a year-on-year increase of 22.
1%; the net profit attributable to shareholders of listed companies was 609 million yuan, a year-on-year increase of 14.
3%; The net profit attributable to shareholders of listed companies before non-recurring profits and losses was 564 million yuan, an increase of 18.
1%
over the same period last year.
According to the data, Laomin is a pharmacy chain store, mainly through its own marketing network to engage in the sale of drugs and health-related goods, which operates products including: Western medicines, Chinese medicine pieces, health preservation Chinese medicine, personal care products, etc.
, in addition, the people also operate some drugs wholesale and production, and DTP professional pharmacy as the main development and many other businesses
。 Liuyao Group Liuyao Group disclosed its third quarterly report on October 16, in the first three months of this year, the company achieved a total operating income of 14.
222 billion yuan, a year-on-year increase of 10.
43%; The net profit attributable to the shareholders of the listed company was 575 million yuan, a year-on-year increase of 15.
40%.

As for the reasons for the growth in performance, the company said that the market share of wholesale and retail has steadily increased, and strengthened the coordination between wholesale and retail, industry and commerce, and effectively promoted the rapid growth of
the industrial sector.
The industrial sector has increased its production capacity scale, accelerated market expansion, and continuously expanded its contribution to the company's profits, which has become a new profit growth point
for the company.
According to the data, the current business of Liuyao Group is mainly composed of
three businesses: pharmaceutical wholesale, pharmaceutical retail and pharmaceutical industry.
Hefu China Hefu China announced on the evening of October 11 that the company's consolidated operating income from January to September was 956 million yuan, an increase of 6.
37%
over the same period last year.
According to the data, Hefu China has established cooperative relations with multi-brand operators, and the intensive business of in vitro diagnostic products can provide in vitro diagnostic reagents and consumables covering nearly 17,000 items from more than 1,000 manufacturers, and has provided intensive procurement services
for in vitro diagnostic products for more than 100 tertiary hospitals.
The medical product circulation business is mainly to act as an agent for overseas innovative medical technology original equipment, and related agent products cover more than 70 hospitals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.